Federal prosecutors filed another high-profile insider trading case Tuesday. A former hedge fund employee allegedly made $276 million for his fund after getting a sneak preview of clinical trial data for a new drug. The investigation may lead to even bigger cases.
Support the news
More NPR or Explore Audio.